Mechanism

TrialResults-center.org

Menu

relaxine

treatment

comparator

All cause death

Cardiovascular death

hospitalisation for heart failure

hospitalisation for cardiovascular causes

CV death, MI hospitalization for HF

death or hospitalization

Cardiovascular death or hospital admission for CHF

heart failure death

BNP under treatment

Serelaxin

heart failure, in acute heart failure

-

-

-

-

-

-

-

-

-

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
hospitalisation for cardiovascular causes	no data
CV death, MI hospitalization for HF	no data
death or hospitalization	no data
Cardiovascular death or hospital admission for CHF	no data
heart failure death	no data
BNP under treatment	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
Pre-RELAX-AHF, 2009	intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily	placebo	Patients hospitalized with acute heart failure

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -